Clinical Efficacy of PD-1 Inhibitors Plus Split-Course Radiotherapy in the First-Line Treatment of Advanced Kidney Cancer: A Randomized Controlled Trial

Table 2

Clinical efficacy.

	Control group (n = 50)	Study group (n = 50)
CR, n (%)	2 (9.09)	6 (27.27)
PR, n (%)	4 (18.18)	7 (31.82)
SD, n (%)	10 (45.45)	7 (31.82)
PD, n (%)	4 (18.18)	2 (9.09)
ORR, n (%)	6 (27.27)	13 (59.09)
χ2	4.539
	0.033